Skip to main content
. Author manuscript; available in PMC: 2022 Apr 30.
Published in final edited form as: Circ Res. 2021 Feb 18;128(9):1240–1254. doi: 10.1161/CIRCRESAHA.120.318155

Figure. 7. TGR5 agonism attenuates elevated blood pressure and improves vascular function in SHRSP.

Figure. 7

(a) SBP measurements in SHRSP injected daily with vehicle or the TGR5 agonist OA. (b) Acetylcholine (Ach_induced vasodilation of mesenteric arteries isolated from vehicle- or OA-treated SHRSPs. (c) Calculated EC50 values for acetylcholine induced vasodilation of mesenteric arteries isolated from vehicle or OA treated SHRSPs. Data presented as mean ± SEM. (a) Two-way ANOVA main effects of age (p<0.0001), treatment (p=0.0317), and age x treatment (p=0.0023). (b) Two-way ANOVA main effects of Ach dose p<0.0001, treatment p=0.0262, dose x treatment p=0.0125. (c) unpaired t-test. *p≤0.05 vs SHRSP vehicle, **p≤0.01 vs SHRSP vehicle, n=5-6